NASDAQ NMS - GLOBAL MARKET · INDV
-3.23% · -$1.26 · Vol 1.4M
After hours · updated 16:00:40 ET
Indivior Pharmaceuticals, Inc

Indivior Pharmaceuticals, Inc

Pharmaceuticals
$37.78
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
Analyst data unavailable at compute time
INDV
Indivior Pharmaceuticals, Inc
Stale score · Wed Aug 19 · completed session · 24h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

70/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Stale score · Wed Aug 19 · completed session · 24h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET
Share on X →
Veridion Score History · 90D
Score not reportedVeridion does not publish a score-history trend for INDV until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
AI Analysis
Sovereign

Why is INDV moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading INDV catalysts
About Indivior Pharmaceuticals, Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2014
Employees
838
Country
US

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$38.91
Day high
$39.25
Day low
$37.64
Previous close
$39.04
52W high
$41.83
-9.68% from high
52W low
$22.51
79% of range
Market cap
$4.6B
P/E
20.64×
EPS
$1.83
Beta
0.06
Shares out
118M
Volume
1.4M
0.67× rel vol
Avg volume
2.2M
VWAP
$38.03
Price history computed in-house
1W
-1.15%
1M
-6.60%
3M
+0.67%
1Y
+56.44%
YTD
+5.30%
SMA 50 $39.58 · below
SMA 200 $35.38 · above
52W position 79%

INDV overview

Veridion Score
Not reported
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around INDV.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading INDV Form 4 filings
Public disclosures

Congress activity in INDV

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for INDV in the cached public ledger.

Federal contracts

INDV contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for INDV in this window.
Lobbying spend

INDV lobbying filings, year to date.

Registered lobbying filings matched to Indivior Pharmaceuticals, Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for INDV in this window.
Loading news for INDV
Analyst ratings
Sovereign unlock shows live analyst consensus for INDV.
Options
Sovereign unlock shows live options positioning for INDV.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.